Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance

The power of immunotherapy in the battle of Multiple Myeloma (MM) started with allogeneic stem cell transplantation, and was rediscovered with immunomodulatory drugs and extended with the outstanding results achieved with targeted antibodies. Today, next to powerful antibodies Elotuzumab and Daratum...

Descripción completa

Detalles Bibliográficos
Autores principales: Holthof, Lisa C., Mutis, Tuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226482/
https://www.ncbi.nlm.nih.gov/pubmed/32316450
http://dx.doi.org/10.3390/cancers12040988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226482/
https://www.ncbi.nlm.nih.gov/pubmed/32316450
http://dx.doi.org/10.3390/cancers12040988

Ejemplares similares